Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 10/20 | 0.37 |
| ▸ | RAB9A | P51151 | 11/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291179 | 0.89 | KDM4E (0.44) | GAANPC1RAB9ATP53KMT2A | |
| SCHEMBL4285598 | 0.83 | GAA (0.41) | GAAKCNH2MCHR2MCHR1NPC1 | |
| SCHEMBL4285430 | 0.81 | GAA (0.42) | GAANPC1RAB9A | |
| SCHEMBL4294945 | 0.81 | SMN1; SMN2 (0.44) | GAATP53KMT2A | |
| SCHEMBL4285461 | 0.77 | GAA (0.43) | GAAKCNH2MCHR2MCHR1NPC1 | |
| SCHEMBL4285120 | 0.76 | NPC1 (0.39) | GAAKCNH2NPC1RAB9AKMT2A | |
| SCHEMBL4282201 | 0.74 | MAN1B1 (0.38) | GAANPC1RAB9ATP53 | |
| SCHEMBL4292964 | 0.73 | MAPT (0.45) | NPC1RAB9AKMT2A | |
| SCHEMBL4285411 | 0.73 | ROCK2 (0.46) | — | |
| SCHEMBL4295533 | 0.72 | ATM (0.43) | NPC1RAB9ATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GAA 1381/4885KCNH2 664/4885MCHR2 3777/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GAA 1381/4885KCNH2 664/4885MCHR2 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.